What The Article Says:
This Viewpoint proposes ways to maximize vaccine efficacy and allocation given the rise of coronavirus variants and authorization of a Johnson & Johnson vaccine, including reserving the latter for younger healthier populations, boosting it with a single-dose messenger RNA (mRNA) vaccination and single mRNA immunization of people with prior documented SARS-CoV-2 infection.
Authors:
John P. Moore, Ph.D., of Weill Cornell Medicine in New York, is the corresponding author.
To access the embargoed study:
Visit our For The Media website at this link
https:/
/
media.
jamanetwork.
com/
(doi:10.1001/jama.2021.3465)
Editor’s Note:
The article includes an Editor’s Note. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
###
Media advisory:
The full article is linked to this news release. A livestream with the author also is scheduled for Thursday at 3:50 P.M. (ET) and will be available here:
http://ja.
ma/
moore0304
Embed this link to provide your readers free access to the full-text article
This link will be live at the embargo time
https:/
/
jamanetwork.
com/
journals/
jama/
fullarticle/
10.
1001/
jama.
2021.
3465?guestAccessKey=
a44d6501-b605-47f2-970e-f8cc12936363&utm_source=
For_The_Media&utm_medium=
referral&utm_campaign=
ftm_links&utm_content=
tfl&utm_term=
030421
This part of information is sourced from https://www.eurekalert.org/pub_releases/2021-03/jn-afo030421.php